If you mostly know AI through chat-style tools and you are trying not to fall behind, this is the part worth saving. When you see 'Using AI to help physicians diagnose rare genetic diseases affecting children,' the easy assumption is that the breakthrough must be a stronger model reading DNA. The better-supported takeaway from current benchmark papers is harsher: the first battleground for pediatric rare disease AI is not genes. It is structuring the medical record.
Why that matters: if you stare only at the flashy gene step, you spend your time and attention on the wrong bottleneck. A system cannot rank genes well if a child's symptoms are still trapped inside messy notes. Before the model can reason, those notes have to become HPO labels, meaning a standard symptom vocabulary the computer can compare across cases. Don't judge an AI update by feature count. Judge it by whether it changes your next decision.
The strongest proof point in this brief follows that exact pipeline: extract findings from clinical records, normalize them into HPO, then rank likely genes. In the cited benchmark, RARE-PHENIX trained on 2,671 patients and was externally validated on 16,357 real clinical records, reaching 0.70 ontology similarity versus 0.58 for PhenoBERT [S001]. Another paper explains why the note-structuring step matters so much: only 2.2% of ICD codes in UMLS map directly to HPO, and in real EHR data fewer than half of ICD codes had HPO mappings [S002].
So the practical read is not 'AI can now solve pediatric rare disease diagnosis from genes.' It is 'without structured notes, the rest of the pipeline starts dirty.' These are public benchmark papers as of 2026, not proof of live hospital deployment or medical advice. Save this if you track medical AI, and share it with the person who still thinks the hard part starts at the gene file.